Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human plasma-derived fibrinolysin - Grifols

Drug Profile

Human plasma-derived fibrinolysin - Grifols

Alternative Names: BAY 57-9602; Fibrinolysin-human - Grifols; Plasmin - Grifols; TAL-05-00018

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Bausch & Lomb; Grifols
  • Class Serine endopeptidases; Thrombolytics
  • Mechanism of Action Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Peripheral arterial occlusive disorders; Stroke
  • Discontinued Eye disorders

Most Recent Events

  • 02 Aug 2019 No development reported - Phase-I/II for Stroke in United Kingdom, Germany, Slovakia, France, Austria, Spain, Serbia, Australia (Intra-arterial) (NCT01014975)
  • 02 Aug 2019 No development reported - Phase-II for Peripheral arterial occlusive disorders in Spain, Romania, Poland, Peru, India, USA, Germany, Czech Republic, Bulgaria, Slovakia, Serbia, Belgium (Intra-arterial) (NCT01222117)
  • 31 Jan 2016 Grifols Therapeutics completes phase II clinical trials in Peripheral arterial occlusive disorders in the US, Belgium, Bulgaria, Czech Republic, Germany, India, Peru, Poland, Romania, Serbia, Spain and Slovakia (Intra-arterial) (NCT01222117)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top